EIN Presswire: Biotechnology Featured Press Releases

EIN News Launches Celgene Daily Report

Wed, 25 Jan 2012 12:16:13 +0000

Washington, January 25, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company since 1995, has announced the launch of Celgene Daily Report.

For more news see:

- Celgene Foundations News - http://celgene.einnews.com/news/celgene-foundations
- Celgene Daily Report - http://celgene.einnews.com/

About the publisher of Celgene Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com

Amarantus BioSciences Licenses Disease Diagnostic Biomarker Test from Power3 Medical Products

Mon, 23 Jan 2012 09:16:17 +0000

Amarantus BioSciences Licenses Parkinson's Disease Diagnostic Biomarker Test from Power3 Medical Products

/EINPresswire.com/ SUNNYVALE, CA and THE WOODLANDS, TX - January 23, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein being developed for the treatment of Parkinson's Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. (OTCBB: PWRM) for the NuroPro(R) Blood Test as it relates to Parkinson's disease diagnosis. Concurrent with the license, Amarantus has raised $100,000 from a private, foreign investor introduced to the Company by www.tomorrowsbluechips.com.

The NuroPro Blood Test is Power3's diagnostic platform for the early detection of neurodegenerative diseases. It is being developed as a tool to assist physicians to more accurately diagnose disease and monitor progression. The platform involves monitoring the concentration of 57 protein markers in blood serum identified to be linked to neurodegeneration in order to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Amarantus' license is focused on the further development of a subset of 21 of these protein markers specifically targeting early diagnosis and ongoing monitoring of Parkinson's disease.
The Parkinson's disease application of the NuroPro Blood Test has completed proof-of-concept and Phase 1 clinical validation studies. Amarantus plans to initiate a Phase 2 clinical validation study in the first half of 2012 that is expected to last approximately six months. Management of the trial will be partnered to Power3 as part of its ongoing strategy to build its Clinical Research Organization business unit.

"The in-license of the NuroPro Blood Test for Parkinson's disease expands our product offering as we strive to become the leader in the evaluation and treatment of Parkinson's disease," said Gerald Commissioning, President and CEO of Amarantus BioSciences. "Now that we will be able to tailor our therapeutic development pathway towards a companion diagnostic product that we control, Amarantus is positioned to build a strategic advantage over competitors as the execution of our clinical and regulatory strategy continues to advance MANF as a disease-modifying treatment for Parkinson's disease. The Company was also recently awarded the composition of matter patent for MANF by the US Patent & Trademark Office, further enhancing our position in the field."
Given the length of time it takes to accurately diagnose Parkinson's disease and the relatively high early misdiagnosis rates, the development of a blood-based biomarker test is likely to generate significant interest among neurologists and primary care physicians as it will allow them to intervene at an earlier stage in disease progression. In addition, the NuroPro Blood test for Parkinson's may generate partnering and revenue opportunities for Amarantus.
The terms of the agreement give Amarantus an exclusive license to develop, manufacture, have manufactured, use, market, sell and import medical devices and methods under the Power3 Parkinson's Disease Intellectual Property (IP). In addition, the license provides Amarantus an exclusive, royalty-free, fully paid-up worldwide license to Power3 know-how, patents and patent applications which relate to medical devices and methods for the treatment of neurodegenerative disease as it relates to Parkinson's disease.

Amarantus paid a $25,000 exclusivity fee in common stock on November 11, 2011 and will issue to Power3 $475,000 worth of common stock. In addition, Amarantus has an option to purchase all of the Parkinson's Disease IP owned by Power3 for $500,000 worth of common stock and maintains a Right of First Refusal to acquire the balance of the NuroPro platform for Alzheimer's, ALS and all other neurodegenerative diseases. The initial term of this License Agreement is for one year and is renewable upon mutual written agreement of the parties.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (OTCBB:PWRM) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and Parkinson's disease.

MEDIA CONTACTS:

Lou Levenstein
info@seraphimstrategies.com
727.489.9939

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Amarantus BioSciences Interview at the 2012 Biotech Showcase

Fri, 20 Jan 2012 10:28:00 +0000

/EINPresswire.com/ SUNNYVALE, CA - January 20, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, was interviewed at the 2012 Biotech Showcase in San Francisco last week. The interview can be accessed via the following link: http://stocknewsnow.com/?p=2825.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

MEDIA CONTACT:

Lou Levenstein
727.489.9939
info@seraphimstrategies.com

TCT Receives Patent on Therapeutic Monoclonal Antibody Targeting Pancreatic Cancer

Tue, 17 Jan 2012 14:08:52 +0000

/EINPresswire.com/ SANTA ROSA, CA, (1/18/12) --Targeted Cancer Therapeutics LLC (TCT) announced that its anti-CEACAM6 product received the U.S. Designation of Patent Number 8,038,996. The patent claims allow for a method of treating various types of cancer using an anti-CEACAM6 monoclonal antibody that induces apoptosis in cancer cells.

"We designed a monoclonal antibody that binds to CEACAM protein over-expressed on >95% of pancreatic cancer patients. CEACAM6 is also over-expressed in colon cancers, as well as breast, lung ovarian cancers and certain childhood leukemias." stated Daruka Mahadevan MD, Ph.D., Chief Scientific Officer of TCT. "It is a highly specific monoclonal antibody designed to disrupt CEACAM6 function and was tailored for a superior safety profile. There is an unmet need for effective treatments of pancreatic cancer, as it is uniformly lethal and new treatment paradigms are urgently needed."

The antibody was designed as a humanized anti-CEACAM6 single chain variable fragment (scFv) based on the murine Mab 13-1. PEGylation of the glycine-serine linker was used to enhance plasma half-life. The scFv bound CEACAM6 with high affinity, exhibited cytotoxic activity and induced dose-dependent PARP-cleavage in KRas mutated and wild type pancreatic cancer cell lines. Murine PDA xenograft models treated with low doses of humanized scFv-PEG alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry of harvested tumors showed significant apoptosis, with inhibition of angiogenesis and proliferation.

In 2010, there were over 40,000 pancreatic cancer cases, of which there were over 39,300 deaths, providing a dismal prognosis. This is attributable to a lack of early diagnosis and effective treatments. Most patients present with unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDA), with a median overall survival of 12 and 6 months respectively.

For more information on Targeted Cancer Therapeutics LLC and its products,
Email info@targetedcancer.com or visit www.targetedcancer.com

About Targeted Cancer Therapeutics (TCT)

Targeted Cancer Therapeutics is a privately held biopharmaceutical company located in California. The company has an exclusive license agreement with the University of Arizona for several products designed for the treatment of cancers. TCT is actively seeking investment capital to further develop its products.

Contact Information

William Mulert
President
(707) 477-7022
bmulert@targetedcancer.com

Geron Corporation Daily Report Launched by EIN News

Mon, 16 Jan 2012 12:14:24 +0000

Washington, January 16, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company published by the IPD Group, has announced the launch of Geron Corporation Daily Report.

For more details see:

- Geron Biotechnology News - http://geron.einnews.com/news/geron-biotechnology
- Geron Corporation Daily Report - http://geron.einnews.com/

About the publisher of Geron Corporation Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com

Genzyme Daily Report Launched by EIN News

Fri, 13 Jan 2012 12:23:18 +0000

Washington, January 13, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company published by the IPD Group, has announced the launch of Genzyme Daily Report.

For more details see:

- Genzyme Genetics News - http://genzyme.einnews.com/news/genzyme-genetics
- Genzyme Daily Report - http://genzyme.einnews.com/

About the publisher of Genzyme Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com

Amarantus BioSciences to be Interviewed on The Big Biz Radio Show

Thu, 12 Jan 2012 22:21:07 +0000

/EINPresswire.com/SUNNYVALE, CA - January 12, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Friday, January 13, 2012 at 1:10 PM PDT. The live broadcast can be accessed via the show's website: http://bigbizshow.com/media/
The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Contact:
Lou Levenstein
727-489-9939
info@seraphimstrategies.com
www.tomorrowsbluechips.com

the challenges associated with obtaining an optimal pharmaceutical portfolio of projects.

Tue, 10 Jan 2012 20:27:34 +0000

SMi presents their 7th annual conference on...
Pharmaceutical Portfolio & Product Lifecycle Management
18th-19th April 2012, The Grange Holborn Hotel, London, United Kingdom

/EINPresswire.com/ With declining R&D costs, prioritizing a portfolio of successful projects has become essential within the pharmaceutical industry. Lifecycle management approaches must be implemented throughout a products developmental and market period to ensure an increase in profit. Ultimately, the success of pharmaceutical companies relies on crucial project portfolio decisions and understanding of a product's lifecycle.

Join SMi at their 7th annual Pharmaceutical Portfolio & Lifecycle Management that will address the challenges associated with obtaining an optimal portfolio of projects. Senior level industry executives will discuss key strategies and management approaches essential to effective portfolio and lifecycle management.

The key speaker line up includes:

Tony Ellery, Managing Director, Ellery Pharma Consulting, Former Global Head LCM in Portfolio Management, Novartis
Kimber Hardy, Head of Valuation and Analysis, Merck Serono
Tim Harris, Director, Respiratory & Immuno-inflammation Portfolio Management, GlaxoSmithKline
Shafique Virani, Global Head CNS Business Development, F. Hoffman La Roche
Sakir Mutevelic, Head of Global Project Management Biopharmaceuticals Hemophilia A/WD, Baxter
Christiano Pereira Silva, Global Product Manager for Pradaxa, Boehringer-Ingelheim
Julie Barrett-Major, Director of Intellectual Property, Norgine
Alan S. Harris, Senior Vice President, Global Projects & Portfolio Management, Ferring Pharmaceuticals
Christine Deuschel, Vice President Portfolio & Project Management, Debiopharm
Anne Lane, Executive Director, University College London Business
Angel Calvo Yague, Healthcare Platform Council Member, Gerson Lehman Group Healthcare & Biomedical Council
Boris Kreye, Lawyer, Bird & Bird
Bruce D Sunstein, Partner, Sunstein Kann Murphy & Timbers LLP
Kerstin Bode-Greuel, Lecturer, University of Essen/PME Institute
Graham Cox, Senior Consultant, IDEA Pharma
Philip Graves, Market Research Consultant, Philip Graves Consultancy
John Ansell, Honorary Consultant, School of Pharmacy and Pharmaceutical Sciences, University of Manchester

For further details and to view a full the conference and list of speakers visit http://www.smi-online.co.uk/pharma-portfolio29.asp

How to best standardise imaging result from multi centre clinical trials

Tue, 10 Jan 2012 20:27:22 +0000

SMi present their 8th annual conference on.........
Imaging in Cancer Drug Development
14-15 March 2012, Copthorne Tara Hotel, London

/EINPresswire.com/ The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new therapeutics has never been greater. Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one. Taking almost 12 years and costly approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time. With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation into human subjects?
Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.
Hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the drug development process. Find out how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardise imaging result from multi centre clinical trials.

Leading speakers include:

• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute of Oncology
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK

View the full programme and find out more details by contacting Andrew Gibbons on tel: +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk.

http://www.smi-online.co.uk/cancer-imaging38.asp

Amarantus BioSciences Releases New Video Interview with President and CEO Gerald Commissiong

Fri, 06 Jan 2012 10:55:18 +0000

/EINPresswire.com/ Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Recently, the biotech company released a video interview with its CEO, Gerald Commissiong that covers its development of MANF. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide range of conditions. Recently, the company updated shareholders on its expanded corporate strategy and execution.

Amarantus BioSciences, Inc. released news on January 3, 2012 providing shareholders with an update on the execution of its expanded corporate strategy first announced on November 1st 2011 to position Amarantus as a neurology-focused biotechnology company. Since that time, the Company has:
Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International;
Recruited seasoned neurology executive Mark Benedyk, PhD to advise the company on strategy and business development efforts;
Received positive feedback on the Company's updated business plan from investors who attended the Company's presentation at the National Investment Banking Association conference in Las Vegas, NV on December 1st, 2011.

"Amarantus has made good progress since the announcement of the Company's expanded corporate strategy, and management will work diligently to cause this trend will continue into 2012," said Gerald Commissiong, Amarantus' newly appointed President and CEO. "We will continue to focus our efforts on securing additional corporate partnerships, improving our pipeline and adding seasoned neurology-focused executives to the executive team in order to diligently build shareholder value and improve the standard of care for patients."
Amarantus believes that it has a unique opportunity to effect meaningful improvements in the treatment of Parkinson's disease for millions of patients worldwide. The Company expects to release additional results to the marketplace from its lead program for Parkinson's disease in the first half of 2012.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Investor Relations Contact:

Seraphim strategies

Lou Levenstein

www.seraphimstrategies.com
www.tomorrowsbluechips.com
727-489-9939

Amarantus BioSciences Updates Shareholders on Execution of Expanded Corporate Strategy

Wed, 04 Jan 2012 09:51:14 +0000

/EINPresswire.com/ SUNNYVALE, Calif. Amarantus BioSciences, Inc. (OTCBB: AMBS.OB - News), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today provided shareholders with an update on the execution of its expanded corporate strategy, first announced on November 1st, 2011, to position Amarantus as a neurology-focused biotechnology company. Since that time, the Company has:
• Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International;
• Recruited seasoned neurology executive Mark Benedyk, PhD to advise the company on strategy and business development efforts;
• Received positive feedback on the Company's updated business plan from investors who attended the Company's presentation at the National Investment Banking Association conference in Las Vegas, NV on December 1st, 2011.

"Amarantus has made good progress since the announcement of the Company's expanded corporate strategy, and management will work diligently to cause this trend will continue into 2012," said Gerald Commissiong, Amarantus' newly appointed President and CEO. "We will continue to focus our efforts on securing additional corporate partnerships, improving our pipeline and adding seasoned neurology-focused executives to the executive team in order to diligently build shareholder value and improve the standard of care for patients."

Amarantus believes that it has a unique opportunity to effect meaningful improvements in the treatment of Parkinson's disease for millions of patients worldwide. The Company expects to release additional results to the marketplace from its lead program for Parkinson's disease in the first half of 2012.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Contact

Seraphim Strategies
www.seraphimstrategies.com

Angel at UNESCO site in France Rocks World for Christmas!

Tue, 20 Dec 2011 07:30:36 +0000

/EINPresswire.com/ December 20th, 2011 Chauvet Cave, France

A Christmas Angel has just been unveiled at the UNESCO Chauvet Cave in southern France. It's profound symbolism was explained by metaphysical scholars Gerald D'Aoust and Daryl Breese. The Pegasus has always been a symbol of the Holy Spirit, Peace and even Santa's original ride/ sleigh horse. Four angelic encounters led the team to this cave art, now the oldest religious relic which has pushed back the dawn of religion another 15,000 years.
The Pegasus is showcased in two murals. One graphic is the first Story of Creation and the other shows animals disembarking from a vessel which has landed on a mountain. Enjoy the graphics, linked below. Breese has posted all the exhaustive details of interpretation 'on line' for the world to enjoy!
http://www.culture.gouv.fr/culture/arcnat/chauvet/en/owpt14.htm
www.culture.gouv.fr/culture/arcnat/chauvet/en/owpt24.htm
http://www.culture.gouv.fr/culture/arcnat/chauvet/img/fond0421.jpg
D'Aoust and Breese just published the non-fiction "God's Steed- Key to World Peace" (Lulu 2011). The Chauvet Pegasus is featured on the book's cover. Like Tom Hanks in the fictional "Angels and Demons", they are the real life 'symbologists' who have discovered this ancient point from which all religion and philosophy have descended. "Cave of Forgotten Dreams" by Werner Herzog was just released in this year and lets us see this earliest cave art. Some report visions after seeing the movie.
Breese believes the common ground of this new discovery connects all the Holy Books and could spawn greater understanding, tolerance and harmony- possibly leading to a peace accord.

Sir Knight Daryl Breese
Nampa, Idaho USA
calbreese@hotmail.com
(661)703-4444

Lab88's Co-Clean Presents the New Year's Skinny Jeans Challenge

Mon, 12 Dec 2011 09:10:01 +0000

/EINPresswire.com/ Do a Colon Cleanse in December and Get Back Into Skinny Jeans by January with Co-Clean Cleanse and Flush Tablets!

Get back into those designer skinny jeans with Lab88's system detoxifier, Co-Clean Cleanse and Flush tablets. Research has shown that this health supplement's unique proprietary formula increases energy levels and enhances overall vitality and it has been specifically designed to detox the digestive system and improve general well-being.

Co-Cleanse is a powerful colon cleaner that contains bulk oat and beetroot fibers, calcium, phosphorous, Apple Cider Vinegar, Cascara sagrada bark, Chitosan, grapefruit extract and Senna. Co-Clean's Skinny Jeans Diet Cleanse program contains a powerful detoxifier which flushes out dangerous toxins, increasing vitality and energy levels. Co-Clean's proprietary blend of cleansing roots and extracts will detox the digestive system, with positive effects being felt in a few days.

Co-Clean contains Apple Cider Vinegar which has been proven to enable weight loss by promoting satiety. The formula also contains Chitosan, which is derived from shellfish and which acts as a fat binder, interacting with lipids and preventing them from being absorbed by the digestive system.

The dried and aged bark of the Cascara sagrada tree has long used by Native Americans as a laxative and it is a widely accepted and effective chronic constipation treatment in the USA. Research into the bark has shown that it contains anthraquinones which interact with the bacteria of the intestines and help paeristalsis and the restoration of digestive tract muscle tone.

Recommended dosage is two tablets and each bottle contains fifty-six tablets, enough for one month. This product is ideal for those following a high protein, low carbohydrate diet and it provides 1. 3 grams of dietary fiber per serving.

To get the full benefits of Co-Clean Cleanse and Flush, it is recommended to take two tablets with 10 ounces of water before going to bed at night. Continue with this routine for a month, which will allow sufficient time for the colon to be cleansed of all toxins. Wait ten to fourteen days before beginning the second cleansing phase.

Side effects may include some nausea, fatigue and headaches initially - this is normal at the beginning of a cleanse and should pass in a few days, followed by an improved sense of wellbeing, vitality and energy, better bowel function and concentration and clearer skin and sinuses.

A one month supply of Co-Clean can be purchased for $49.99 but when purchasing two bottles for the special price of $99.98, another bottle is free, as well as a complimentary DVD.

Order Co-Clean Cleanse and Flush Tablets today and enjoy more energy and better health!

About Lab88.com
Lab88 is a company founded with the mandate to create first grade supplements and health products. You can locate them at www.lab88.com or contact them via their toll free number: 1-888 LOOK NICE or 1-888 566-5642. Lab88 products are made in the USA in cGMP Certified Labs. What is a cGMP lab? It means that the Manufacturing plant meets FDA Pharmaceutical and GMP (Good Manufacturing Practices) standards. According to GMP, each product must pass 26 steps staging from the raw material to the finished product.

###

Media Contact
Rich Fuchs
http://www.co-clean.com/index.asp/?s=pr
888.look.nice
888.566.5642 Ext. 106

Press Release Courtesy of Online PR Media: http://bit.ly/uMQ77D

Amarantus BioSciences to Present (NIBA) 120th Investment Conference

Fri, 02 Dec 2011 08:21:58 +0000

IR Sense
Remy Barnarda
Remy@irsense.com
415.203.6386

Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA) 120th Investment Conference

/EINPresswire.com/ SUNNYVALE, CA- December 1, 2011 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a first-in-class disease-modifying therapeutic protein, today announced that it has been selected to present at 120th National Investment Banking Association's Conference in Las Vegas, NV at Caesar's Palace on Thursday, December 1st at 10:10am Pacific.

NIBA is the only national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8000 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.

NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, and give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure, collectively voice their positions on issues impacting the securities industry, and enhance their knowledge and expertise through ongoing education programs designed to enable them to remain competitive in today's financial market.

EVENT INFORMATION AT A GLANCE:

WHO: Gerald Commissiong, President and Chief Executive Officer
WHEN: November 30, 2011 - December 2, 2011
WHERE: Caesars Palace Las Vegas Hotel & Casino- 3570 Las Vegas Blvd South, Las Vegas, NV

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

http://tomorrowsbluechips.com/

Webcast Interview (OTCBB: AMBS) Amarantus BioSciences, Inc

Tue, 29 Nov 2011 06:40:09 +0000

New Webcast Interview with President and CEO Gerald Commissiong (OTCBB: AMBS) Now Available at TheGreenBaron.com; The Green Baron Report Makes AMBS New "Stock Pick"

/EINPresswire.com/ SUNNYVALE, CA - November 29, 2011 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, announces today that its President and CEO Gerald Commissiong has conducted an exclusive new audio-taped webcast interview so that AMBS shareholders and the investment community can learn more about the Company's recent developments and growth plans. Unrestricted access to the webcast is now available on the "Webcasts" page at www.TheGreenBaron.com. Investors who wish to receive The Green Baron Report for free can join at http://www.thegreenbaron.com/Join.htm.

The Green Baron Report also released a new "Stock Pick" report on AMBS yesterday after the close of trading to its members by email and posted the 17-page report on its website. The report states, "MANF represents a potential treatment for a range of diseases including Parkinson's, and the Company last month received its Notice of Allowance from the United States Patent & Trademark Office." It goes on to say, "Due to the fact that there is currently no cure for Parkinson's, any treatment demonstrating efficacy and safety could get fast tracked through the FDA testing and clearance process."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

About The Green Baron Report

The Green Baron Report is a subsidiary of Evergreen Marketing. The Green Baron Report is an internet stock market newsletter that focuses on low priced stocks that appear to have significant upside potential. For more information about Evergreen Marketing, Inc. and their subsidiary The Green Baron Investors Society visit them on the web at http://www.EvergreenMarketingInc.com and http://www.TheGreenBaron.com or http://www.StrictlyStocks.com. Our disclaimer can be viewed at http://www.thegreenbaron.com/Disclaimer.htm.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Contact:

Amarantus BioSciences, Inc.
Gerald E. Commissiong, 408-737-2734, ext. 102
pr@amarantus.com